Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.

The gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

The Macrogen-backed gut microbiome drug developer went public in a $22.5m offering priced at the foot of its range.

The China Resources and Legend Holdings-backed vaccine technology developer floated in Hong Kong in a $97.7m offering following nearly $460m in funding.

The multicorporate-backed diversified mobile app operator has listed on IDX having priced its shares at near the top of their range.

The Brii Biosciences-backed lung disease treatment developer priced an upsized offering in the middle of its range.

Data analytics engineering group DBT Labs closed a $222m series D round including several corporates while 4Paradigm has filed an IPO prospectus again after its earlier attempt expired.

The blockchain payment platform developer’s valuation through its imminent reverse takeover has doubled, buoyed by the popularity of its stablecoin.

The NEC-backed quantum computing system developer is set to list on the New York Stock Exchange through the transaction.

SoftBank Vision Fund 2 led a $300m round for business-to-business marketplace ElasticRun and co-led blockchain creation platform developer Aleo's $200m series B.